+44 20 3868 9735
National Cancer Center Hospital Japan
Dr Kohei Shitara is staff doctor of Department of Experimental Therapeutics (and Gastrointestinal Oncology), National Cancer Center Hospital East, Kashiwa in Japan. He received his medical degree from Tohoku University School of Medicine in 2002.Ã£â¬â¬ Dr Shitara is an active member of American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO). He is also a member of the Japanese Society of Internal Medicine, the Japanese Society of Medical Oncology (JSMO), the Japanese Society of Clinical Oncology (JSCO), the Japanese Gastric Cancer Association, Protocol Review Committee of Japanese Clinical Oncology Group (JCOG), West Japanese Oncology Group (WJOG). He also acts as one of the members for Japanese guideline for Gastric Cancer. Dr Shitara’s main research interests include development of new anti-cancer agents, optimal chemotherapy regimen for gastrointestinal cancer, and translational research through the development of molecular targeted agents. He is the primary investigator or study coordinator for “Randomized phase II trial of FOLFIRI with either panitumumab or bevacizumab as second-line treatment in patients with KRAS wild metastatic colorectal cancer refractory to oxaliplatin and bevacizumab(WJOG6210G) (UMIN000005216)”, “Randomized Phase II Study Comparing Dose Escalated Weekly Paclitaxel versus Standard Dose Weekly Paclitaxel for Patients with Previously Treated Advanced Gastric Cancer (UMIN0000040556)”, “Randomized trial comparing resection of primary tumor plus chemotherapy with chemotherapy alone in incurable Stage IV colorectal cancer (JCOG1007, PI of chemotherapy part) “, “Phase I trial of Stem Cell inhibitor for gastric cancer) (UMIN000010254)”,‘’Randomised study of regorafenib and cetuximab, REVERECE trial (UMIN000011294)’’. He has reported more than 80 peer review publications as 1st author and co-author in these fields and contributed significantly to the development of cancer therapy.
Dr Shitara’s main research interests include development of new anti-cancer agents, optimal chemotherapy regimen for gastrointestinal cancer, and translational research through the development of molecular targeted agents.